FDA Approves LEROCHOL Autoinjector for Once-Monthly Self-Administration in Patients With High Cholesterol
LIB Therapeutics, Inc. (LIB), a privately held biopharmaceutical company focused on helping high-risk patients achieve and maintain recommended cholesterol levels, announced that the U.S. Food and Drug Administration (FDA) has approved a new autoinjector presentation for LEROCHOL® (lerodalcibep-liga) Injection 300 mg/1.2 mL.
The approval adds a single-use autoinjector to the available administration options for LEROCHOL, a third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor designed to provide substantial and sustained low-density lipoprotein cholesterol (LDL-C) reduction with once-monthly dosing. The FDA also approved an update to the LEROCHOL prescribing information to reflect evidence linking LDL-C reduction achieved with statins and monoclonal antibody PCSK9 inhibitors used in combination with statin therapy to a reduced risk of major adverse cardiovascular events (MACE).
The new autoinjector is intended to simplify self-administration and provide patients with an additional option for incorporating LEROCHOL into their long-term cholesterol-management routines. LIB Therapeutics expects the autoinjector to become available in the United States in January 2027, subject to the company’s commercial launch plans.
New Autoinjector Designed for Simple Monthly Administration
The FDA-approved LEROCHOL autoinjector is a single-use device designed to provide a complete dose through a straightforward administration process. The device is pressure-activated and can deliver the medication in seconds through a single motion.
The company believes the new presentation could make monthly treatment easier for patients who need long-term LDL-C reduction. LEROCHOL remains available in a pre-filled syringe, giving healthcare professionals and patients the flexibility to choose between administration formats.
According to LIB Therapeutics, LEROCHOL is designed to combine potent LDL-C lowering with a dosing schedule intended to reduce treatment burden. Patients administer a single injection once a month, rather than having to manage more frequent injectable dosing.
The company also highlights the storage characteristics of LEROCHOL. The medicine can be stored at room temperature for up to 90 days, providing additional flexibility for patients who travel for work, vacations or other extended periods.
This combination of monthly dosing, self-administration and extended room-temperature storage is intended to address practical challenges associated with long-term treatment adherence.
Addressing the Importance of LDL-C Reduction
Elevated LDL-C is an important modifiable risk factor for cardiovascular disease. For patients at elevated cardiovascular risk, reducing LDL-C is a central component of preventive treatment strategies.
Statins remain a cornerstone of cholesterol management. However, some patients are unable to reach recommended LDL-C targets despite receiving maximally tolerated statin therapy. Others may require additional LDL-C reduction because of their underlying cardiovascular risk or genetic conditions such as heterozygous familial hypercholesterolemia (HeFH).
PCSK9 inhibitors have emerged as an important treatment class for patients who need additional LDL-C lowering. By targeting PCSK9, these therapies can increase the availability of LDL receptors involved in removing LDL-C from the bloodstream.
LIB Therapeutics said the updated LEROCHOL indication reflects the broader clinical evidence demonstrating that LDL-C reduction is associated with a lower risk of major cardiovascular events in adults at increased risk when treated with statins or monoclonal antibody PCSK9 inhibitors as an add-on to statin therapy.
Evan Stein, M.D., Ph.D., Founder, Chief Executive Officer and Chief Scientific Officer of LIB Therapeutics, said decades of clinical research have established the connection between LDL-C lowering and cardiovascular risk reduction.
He noted that clinical evidence involving statins and PCSK9 inhibitors has contributed to increasingly aggressive LDL-C treatment goals for patients who remain above guideline-directed targets despite conventional therapy.
Focus on Long-Term Treatment Adherence
For LIB Therapeutics, the development of the LEROCHOL autoinjector represents an effort to address not only the effectiveness of LDL-C lowering but also the practical realities of long-term treatment.
Cholesterol management is often a lifelong process. Patients may need to remain on lipid-lowering therapies for many years to maintain lower LDL-C levels and reduce their cardiovascular risk. Consequently, the ease and convenience of a treatment can influence whether patients continue therapy over time.
LIB designed LEROCHOL around several patient-oriented features, including once-monthly administration and the ability to self-administer the medication. The newly approved autoinjector is intended to further simplify the injection process.
The company believes that reducing the number of injections patients need to administer and making the process faster could help integrate treatment into daily life without requiring major changes to existing routines.
Kristen Miller, Vice President of Brand Communications at LIB Therapeutics, said innovation in PCSK9 inhibition extends beyond the drug itself and includes how treatment fits into patients’ everyday lives.
The company highlighted that monthly LEROCHOL administration does not interfere with oral medications, require overnight fasting or impose restrictions on the timing of food and beverages. The room-temperature storage option is also intended to give patients additional flexibility while traveling.
Physician Highlights Convenience and Efficacy
Dean J. Kereiakes, M.D., FACC, MSCAI, Chairman of The Christ Hospital Heart and Vascular Institute and Professor of Medicine at the University of Cincinnati, emphasized the importance of adherence in obtaining the long-term benefits associated with LDL-C reduction.
According to Kereiakes, PCSK9 inhibitors represent a major advancement in cardiovascular medicine, but their clinical value depends on patients continuing treatment as prescribed.
He said patients increasingly expect therapies to provide both strong efficacy and safety while also fitting into busy lifestyles. In his view, LEROCHOL’s once-monthly administration offers an attractive option for patients who require substantial LDL-C reduction.
The addition of the autoinjector is expected to provide another layer of convenience by simplifying the administration process.
Planned U.S. Availability in 2027
LIB Therapeutics plans to make the LEROCHOL autoinjector available in the United States beginning in January 2027.
The company expects insurance coverage for LEROCHOL to expand progressively throughout 2027. At launch, the autoinjector is expected to be offered alongside the existing pre-filled syringe through LIB’s direct-to-patient cash-pay program.
The company’s stated cash-pay price is $199 per month. LEROCHOL requires a prescription from a licensed healthcare professional.
LIB Therapeutics said it will provide additional information regarding the timing of commercial availability, access pathways and patient support programs as those plans are finalized.
Patients and healthcare providers seeking additional information about LEROCHOL and the company’s LEROCHOL Direct cash-pay program can consult the company’s official patient and healthcare professional resources.
Safety Profile Remains Consistent With Clinical Experience
The company also provided important safety information associated with LEROCHOL.
In clinical trials involving adults with primary hyperlipidemia, including patients with HeFH, the most commonly reported adverse reactions occurring in at least 2% of LEROCHOL-treated patients and more frequently than in placebo-treated patients included nasopharyngitis, injection-site reactions and peripheral edema.
Nasopharyngitis occurred in 15% of patients receiving LEROCHOL and 14% of those receiving placebo. Local injection-site reactions were reported in 12% of LEROCHOL-treated patients compared with 5% of placebo-treated patients. Peripheral edema occurred in 2% of LEROCHOL patients compared with less than 1% of patients receiving placebo.
In clinical trials specifically involving patients with HeFH, injection-site reactions occurred in 18% of patients receiving LEROCHOL compared with 3% of those receiving placebo. Nasopharyngitis occurred in 13% and 9% of patients, respectively. Diarrhea was reported in 3% of LEROCHOL-treated patients versus 1% of placebo-treated patients, while nausea occurred in 2% and 0%, respectively. Peripheral edema occurred in 2% of LEROCHOL-treated patients compared with less than 1% of placebo-treated patients.
Injection-site reactions were also the most frequent adverse reaction leading to treatment discontinuation in clinical trials involving adults with primary hypercholesterolemia. Discontinuation because of injection-site reactions occurred in approximately 1% of LEROCHOL-treated patients compared with 0% of placebo-treated patients.
Immunogenicity Considerations
LEROCHOL is a recombinant fusion protein, and as with other therapeutic proteins, there is a potential for immunogenicity.
The possibility of immune responses is an important consideration when evaluating biologic therapies. Healthcare professionals should review the full prescribing information when considering LEROCHOL for individual patients and monitor patients in accordance with established clinical practice and prescribing guidance.
Indication for LEROCHOL
LEROCHOL is indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including individuals with heterozygous familial hypercholesterolemia.
The updated labeling also incorporates the cardiovascular outcomes evidence supporting the relationship between LDL-C reduction and reduced risk of major adverse cardiovascular events in adults at increased cardiovascular risk when treated with statins or monoclonal antibody PCSK9 inhibitors as an add-on to statin therapy.
The updated indication language reinforces the importance of LDL-C management as part of comprehensive cardiovascular risk reduction.
Expanding Treatment Flexibility for Patients
The FDA’s approval of the LEROCHOL autoinjector gives patients and healthcare providers an additional way to administer a therapy intended for long-term LDL-C management.
The company’s strategy centers on combining sustained LDL-C reduction with features designed to minimize treatment burden. Monthly dosing, self-administration, room-temperature storage for up to 90 days and the availability of a pre-filled syringe are intended to provide flexibility for patients with different preferences and lifestyles.
For patients who struggle to reach recommended LDL-C levels with statins alone, additional therapies can play an important role in cholesterol management. The introduction of the LEROCHOL autoinjector could potentially make monthly PCSK9 inhibition more convenient for patients who require ongoing treatment.
With the U.S. launch planned for January 2027 and expected expansion of insurance coverage throughout the following year, LIB Therapeutics is preparing to broaden access to the new delivery option. The company plans to provide additional information regarding commercial availability, affordability initiatives and patient support services as the launch approaches.
Overall, the FDA approval represents a significant product-development milestone for LIB Therapeutics. By adding a single-use autoinjector to LEROCHOL’s existing pre-filled syringe presentation, the company aims to make long-term LDL-C management more convenient while maintaining the therapy’s once-monthly treatment schedule. The updated labeling further reflects the established clinical importance of LDL-C reduction in lowering cardiovascular risk, strengthening the role of effective lipid management for adults who require additional therapy beyond diet, exercise and standard statin treatment.
About LEROCHOL® (lerodalcibep-liga)
LEROCHOL is a novel, small protein-binding, third-generation PCSK9 inhibitor, and has been developed as a convenient, once-monthly, self-administered, single small-volume, subcutaneous injection with extended room temperature stability up to three months. These features make LEROCHOL a unique alternative to other PCSK9 inhibitors. The anti-PCSK9 binding domain of LEROCHOL is an 11-kDa polypeptide called an adnectin, engineered for high-affinity subnanomolar binding to human PCSK9, and fused to human serum albumin to enhance plasma half-life.
About the LIBerate Clinical Trial Program™
The FDA approval of LEROCHOL was based on data from the comprehensive global Phase 3 LIBerate Clinical Trial Program, which enrolled a diverse population of over 2,900 patients with cardiovascular disease (CVD), without CVD at very high and high risk for CVD, including heterozygous and homozygous familial hypercholesterolemia (HeFH). LEROCHOL was dosed once monthly for up to 52 weeks in these key registration-enabling, placebo-controlled trials, and over 2,400 patients continued in the 72-week open-label extension trial.
In clinical trials, LEROCHOL demonstrated sustained LDL-C reductions of ≥60% in patients with, or at very high or high risk of, cardiovascular disease and ≥59% in those with HeFH who have more severe LDL-C elevations. LEROCHOL was generally well tolerated across the LIBerate Clinical Trial Program, with no serious treatment-related adverse events reported in the long-term extension studies.
About LIB Therapeutics, Inc.
LIB Therapeutics is a privately held, commercial-stage biopharmaceutical company dedicated to bringing novel, highly effective, and safe therapies to help the millions of patients with cardiovascular disease and familial hypercholesterolemia finally achieve their LDL-C goals. The company has also submitted a Marketing Authorization Application to the European Medicines Agency, with anticipated approval in 2H 2026. In Greater China, a Biologics License Application has been submitted, with potential approval in 2027. LIB is pursuing additional regulatory submissions in other markets worldwide.